Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)

BACKGROUND: Bezlotoxumab (BEZ) and actoxumab (ACT) are monoclonal antibodies against C. difficile toxins B and A, respectively. Patients receiving a single infusion of BEZ alone or with ACT in the MODIFY I/II trials showed an absolute 10% (relative ~40%) reduction in rCDI over 12-weeks compared with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Dorr, Mary Beth, Zeng, Zhen, Wilcox, Mark, Li, Junhua, Poxton, Ian, Zhao, Hailong, Li, Xiaoyun, Guris, Dalya, Shaw, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631366/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.967
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky